Clinical trials: Schizophrenic Disorder
Schizophrenia
Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia
This study will compare the effectiveness of three treatments in improving medication adherence, symptoms, and function in people with schizophrenia.
- Trial name
- NCT00455663
- Testing
- Cognitive Adaptation Training, Pharm-Cognitive Adaptation Training, Treatment as usual
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Psychotic Disorder NOS
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
The primary objective of this study is to determine if NAC, added to existing antipsychotic treatment, is superior to placebo for cortical erosion in patients with early stage psychosis.
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Trial name
- Breier-Stanley (NCT01339858)
- Testing
- N-Acetyl Cysteine, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophrenia
Aripiprazole, Abilify Maintena Collaborative Clinical Protocol
An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital…
- Trial name
- NCT02717130
- Testing
- Aripiprazole
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Florida Atlantic University
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
- Trial name
- NCT03198078
- Testing
- Brexpiprazole (OPC-34712), Aripiprazole
- Where
- United States
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Modafinil Effects on Cognition in Schizophrenia Patients
Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This includes many types of cognitive dysfunction, such as in attention, memory and language.
- Trial name
- InO (NCT00711464)
- Testing
- modafinil (M1, M2, M4)
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Schizophrenia
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with…
- Trial name
- NCT02203838
- Testing
- RBP-7000
- Where
- 48 sites in United States
- Volunteers
- 500 people
- Sponsor
- Indivior Inc.
Schizophrenia
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013).
- Trial name
- NCT05211947
- Testing
- Iclepertin
- Where
- 303 sites in United States, Argentina and 38 more
- Volunteers
- 1,356 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia Prodrome
Glycine vs Placebo for the Schizophrenia Prodrome
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.
- Trial name
- NCT00291226
- Testing
- Glycine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Yale University
Schizophrenia
Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia is a devastating and complex illness, with multiple symptom and behavioral manifestations. Antipsychotic medications are the mainstay of treatment; however, many patients only partially respond to treatment.
- Trial name
- NCT02118610
- Testing
- L-tetrahydropalmatine (30mg), Sugar pill
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
To assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of patients with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text…
- Trial name
- NCT01795547
- Testing
- Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
- Where
- 2 sites in United States
- Volunteers
- 295 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizophreniform Disorder
DECIFER: Depression and Citalopram In First Episode Recovery
This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients.
- Trial name
- DECIFER (NCT01041274)
- Testing
- Citalopram, Psychoeducation, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Schizophrenia, Schizoaffective
An Open Trial of Cysteamine Treatment in Schizophrenia
The purpose of this study is to determine the tolerability of the medication cysteamine bitartrate on schizophrenia patients and to evaluate the effect of the medication on the symptoms of schizophrenia.
- Trial name
- NCT01139125
- Testing
- (Cystagon) Cysteamine Bitartrate
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Augusta University
Schizophrenia
Safety and Tolerability of Risperidone Implants
A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
- Trial name
- NCT02773576
- Testing
- Risperidone implant
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Braeburn Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Theta Burst Stimulation for Schizophrenia
Purpose and objective Schizophrenia is a chronic debilitating illness with cognitive deficits that cause serious impairment in psychosocial recovery and with few treatments to remediate these deficits.
- Trial name
- NCT03288779
- Testing
- Theta Burst Stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Schizophrenia, Schizoaffective Disorder
Systematic Evaluation of Antiviral Medication in Schizophrenia
The purpose of this study is to examine whether antiviral medication will help improve psychotic symptoms and cognition in individuals early in the course of schizophrenia or schizoaffective disorder who are exposed to herpes…
- Trial name
- SEAMS (NCT00514449)
- Testing
- Valacyclovir
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Konasale Prasad
Schizophrenia
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas…
- Trial name
- NCT00934635
- Testing
- Paliperidone ER, Oral risperidone, PET Scan
- Where
- Germany
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag G.m.b.H
Schizophrenia, Bipolar I Disorder
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)
This study is an open label, sequential-group, two site, multiple dose escalating study of sublingual administered asenapine in a pediatric population with schizophrenia or bipolar I disorder; in one study cohort (3a)…
- Trial name
- NCT01206517
- Testing
- Asenapine 2.5 mg, Asenapine 5 mg, Asenapine 10 mg
- Volunteers
- 30 people
- Sponsor
- Organon and Co
Schizophrenia
Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
The study investigates the use of Atomoxetine in combination with exercise and a diet support group (Weight Watchers)to treat weight gain associated with Olanzapine or clozapine.
- Trial name
- NCT00176436
- Testing
- Diet support group, Group counseling and exercise
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Maryland, Baltimore
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute